65analytes
2orderable panels
1platform
Five clinical situations in which measuring a drug concentration adds information beyond qualitative detection: a narrow therapeutic window, concentration-dependent toxicity, variation in exposure at the same prescribed dose from metabolizer status or hepatic function, the relationship between a parent drug and its confirmatory metabolite, and distinguishing non-adherence from non-response. Each is listed with the analytes on the panel to which it applies.
Five situations in which the number answers what a positive cannot.

Method

LC-MS/MS — definitive toxicology

Liquid chromatography–tandem mass spectrometry

Definitive identification and quantitation of drugs and their metabolites. Each analyte is separated chromatographically and confirmed by a mass-to-charge transition specific to that molecule, then reported as a measured concentration against a cutoff set for that analyte — not as a presumptive positive or negative.

Orderable panels 2

  • Definitive confirmation — selected classes components bill separately

    Clinical testing for patient management. Not employment, legal, or forensic testing. Specimens are not collected under chain of custody.

  • Hormone profile — Mitra microsample components bill separately

    A serum cortisol identifies a signal; it does not diagnose adrenal insufficiency, which requires dynamic testing. Results indicating a finding warrant endocrine evaluation.

Every test in this line

The catalog lists all 65 analytes with method, specimen, codes, and reportable range or cutoff.

Browse the definitive toxicology catalog